New hope for kids with tough leukemia: testing an easier injection
NCT ID NCT07134088
Summary
This study is testing a new, easier-to-administer form of a drug called blinatumomab in children under 12 with a difficult type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). The drug is given as a shot under the skin and aims to help children whose cancer has come back, hasn't responded to treatment, or who still have tiny amounts of cancer cells after therapy. The main goals are to see if this method is safe and if it can help clear the cancer from the bone marrow.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kanagawa Childrens Medical Center
RECRUITINGYokohami-shi, Kanagawa, 232-8555, Japan
-
Seattle Childrens Hospital
RECRUITINGSeattle, Washington, 98105, United States
-
St Jude Childrens Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Conditions
Explore the condition pages connected to this study.